Adiso Therapeutics Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$70M
- Investors
-
2
Adiso Therapeutics General Information
Description
Developer of novel therapeutics designed to treat inflammatory diseases with improved safety and efficacy. The company platform offers a pipeline of multi-modal agents, including gut-restricted neutrophil modulators and inflammasome inhibitors, enabling patients with ulcerative colitis, respiratory conditions, and neuroinflammatory diseases to achieve better treatment outcomes.
Contact Information
Website
www.adisotx.comCorporate Office
- 1188 Centre Street
- Newton Centre
- Newton, MA 02459
- United States
Corporate Office
- 1188 Centre Street
- Newton Centre
- Newton, MA 02459
- United States
Adiso Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 01-Jan-2022 | $70M | Completed | Clinical Trials - Phase 2 | ||
| 2. Early Stage VC (Series A) | 10-Mar-2022 | Completed | Clinical Trials - Phase 2 | |||
| 1. Merger of Equals | 10-Mar-2022 | Completed | Clinical Trials - Phase 2 |
Adiso Therapeutics Patents
Adiso Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025085674-A1 | Methods and compositions for the treatment of ulcerative colitis | Inactive | 20-Oct-2023 | ||
| EP-4680258-A1 | Bacillus amyloliquefaciens strains art12 and art24 for the treatment of disorders of the cns | Pending | 17-Mar-2023 | ||
| WO-2024194737-A1 | Bacillus amyloliquefaciens strains art12 and art24 for the treatment of disorders of the cns | Inactive | 17-Mar-2023 | ||
| WO-2024097229-A1 | Probenecid compounds for the treatment of inflammasome-mediated dermatological conditions | Inactive | 04-Nov-2022 | ||
| WO-2024047527-A1 | Methods and compositions for preventing and treating chemotherapy-induced peripheral neuropathy | Inactive | 01-Sep-2022 | A61K35/742 |
Adiso Therapeutics Signals
Adiso Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bacainn Therapeutics | Corporation | Majority | ||
| Morningside Group | Venture Capital | Majority |
Adiso Therapeutics Acquisitions (2)
Adiso Therapeutics’s most recent deal was a Merger/Acquisition with Artugen Therapeutics. The deal was made on 10-Mar-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Artugen Therapeutics | 10-Mar-2022 | Merger/Acquisition | Drug Discovery | ||
| Bacainn Therapeutics | 10-Mar-2022 | Merger/Acquisition | Drug Discovery |
Adiso Therapeutics FAQs
-
When was Adiso Therapeutics founded?
Adiso Therapeutics was founded in 2022.
-
Where is Adiso Therapeutics headquartered?
Adiso Therapeutics is headquartered in Newton, MA.
-
What is the size of Adiso Therapeutics?
Adiso Therapeutics has 18 total employees.
-
What industry is Adiso Therapeutics in?
Adiso Therapeutics’s primary industry is Drug Discovery.
-
Is Adiso Therapeutics a private or public company?
Adiso Therapeutics is a Private company.
-
What is Adiso Therapeutics’s current revenue?
The current revenue for Adiso Therapeutics is .
-
How much funding has Adiso Therapeutics raised over time?
Adiso Therapeutics has raised $130M.
-
Who are Adiso Therapeutics’s investors?
Bacainn Therapeutics and Morningside Group have invested in Adiso Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process